ArticleAdvances in rheumatology (London, England)2026
Irisin and myostatin serum levels in patients with established rheumatoid arthritis: correlation with radiographic progression and lean body mass.
Article in Advances in rheumatology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe myokines irisin and myostatin participate in bone and skeletal muscle homeostasis and may characterize the clinical status of these tissues. The study aimed to evaluate the association of myokines serum levels with one-year radiographic progression and lean mass in individuals with rheumatoid arthritis (RA).
methodsForty female individuals with RA, aged ≥ 18 years who met 2010 American College of Rheumatology criteria, and 30 individuals without RA and any chronical disease, matched by sex and body mass index (BMI) were included. Serum levels of irisin and myostatin were determined by immune assay. RA subjects had their radiographs of hands and feet evaluated by Sharp/van der Heijde score (SHS) at two timepoints, baseline and after one year. At baseline, disease activity was calculated by Disease Activity Score 28-C reactive protein (DAS28-CRP), body composition was evaluated using dual X-ray absorptiometry (DXA), muscle strength was assessed by handgrip test and chair rising test (CRT), and physical function was assessed by Health Assessment Questionnaire-Disability Index (HAQ-DI) and timed up and go (TUG) test.
resultsMean age of individuals was 56 ± 7.8 years, mean DAS28-CRP was 3.3 ± 1.3, mean disease duration was 11.2 ± 9.2 years, and mean BMI was 28.1 ± 5.1 kg/m
conclusionsLong-term RA was related with higher SHS and lower ALMI, and the late disease stage of included individuals possibly masked the association of myokines with one-year radiographic progression or low lean mass. Otherwise, bDMARDs treatment influenced myokines circulating levels, specifically irisin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.